Paper16640493
Nanoparticle-aptamer bioconjugates for cancer targeting.
Farokhzad OC and 2 others. Expert Opin Drug Deliv, 2006. Cited by 182 papers, by iCite.
Cite this record
ConductScience Library. Nanoparticle-aptamer bioconjugates for cancer targeting. Papers, record 16640493. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16640493
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aptamers, Nucleotide | Major topic |
| Drug Delivery Systems | Major topic |
| Nanostructures | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Delayed-Action Preparations | |
| Humans | |
| SELEX Aptamer Technique | |
| Surface Properties |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 119349 | NCI NIH HHS | United States | U54CA119349 | PubMed and NIH | NIH RePORTER |
| EB003647 | NIBIB NIH HHS | United States | K08EB003647 | PubMed and NIH | NIH RePORTER |
Cited by75
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 182 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41438702 | mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41438702 | PubMed |
| 40873364 | Next-generation Mesoporous Silica Nanoparticles: Precision-engineered Platforms for Ovarian Cancer Therapy. | Curr Drug Res Rev | 2026 | https://conductscience.org/library/papers/40873364 | PubMed |
| 39891600 | Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms and in vivo potential. | Drug Deliv | 2025 | https://conductscience.org/library/papers/39891600 | PubMed |
| 39757607 | Precision Oncology: Advances in Drug Delivery and Imaging. | Recent Adv Drug Deliv Formul | 2025 | https://conductscience.org/library/papers/39757607 | PubMed |
| 39434968 | Progressive cancer targeting by programmable aptamer-tethered nanostructures. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39434968 | PubMed |
| 38898204 | Development, Optimization, and in vitro Evaluation of Silybin-loaded PLGA Nanoparticles and Decoration with 5TR1 Aptamer for Targeted Delivery to Colorectal Cancer Cells. | AAPS PharmSciTech | 2024 | https://conductscience.org/library/papers/38898204 | PubMed |
| 38005286 | HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44. | Molecules | 2023 | https://conductscience.org/library/papers/38005286 | PubMed |
| 36839929 | Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36839929 | PubMed |
| 36547533 | Metal Oxide Nanoparticles: Review of Synthesis, Characterization and Biological Effects. | J Funct Biomater | 2022 | https://conductscience.org/library/papers/36547533 | PubMed |
| 36376604 | TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems. | Pharm Res | 2023 | https://conductscience.org/library/papers/36376604 | PubMed |
| 36341415 | Targeted delivery of liposomal chemoimmunotherapy for cancer treatment. | Front Immunol | 2022 | https://conductscience.org/library/papers/36341415 | PubMed |
| 36145668 | "Targeting Design" of Nanoparticles in Tumor Therapy. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36145668 | PubMed |
| 36015307 | Functional Nanoparticles for Enhanced Cancer Therapy. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015307 | PubMed |
| 36015276 | Selective Targeting and Eradication of Various Human Non-Small Cell Lung Cancer Cell Lines Using Self-Assembled Aptamer-Decorated Nanoparticles. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015276 | PubMed |
| 35857350 | From Bench to Cell: A Roadmap for Assessing the Bioorthogonal "Click" Reactivity of Magnetic Nanoparticles for Cell Surface Engineering. | Bioconjug Chem | 2022 | https://conductscience.org/library/papers/35857350 | PubMed |
| 35642539 | Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? | Chem Soc Rev | 2022 | https://conductscience.org/library/papers/35642539 | PubMed |
| 34424426 | Zebrafish: A Promising Real-Time Model System for Nanotechnology-Mediated Neurospecific Drug Delivery. | Nanoscale Res Lett | 2021 | https://conductscience.org/library/papers/34424426 | PubMed |
| 34349972 | Precision photothermal therapy and photoacoustic imaging by in situ activatable thermoplasmonics. | Chem Sci | 2021 | https://conductscience.org/library/papers/34349972 | PubMed |
| 33266216 | Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33266216 | PubMed |
| 33228250 | Aptamer-Functionalized Natural Protein-Based Polymers as Innovative Biomaterials. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/33228250 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16640493
GET https://conductscience.org/api/papers/v1/16640493/cited_by?page=2